| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
N-Acetyl-Ser-Asp-Lys-Pro is particularly destroyed by ACE, and its plasma levels increase considerably with ACE inhibitor treatment. Flow cytometry of rat cardiac fibroblasts treated with N-Acetyl-Ser-Asp-Lys-Pro indicated that cell progression from the G0/G1 phase of the cell cycle to the S phase was significantly slowed. Furthermore, Smad2 phosphorylation and nuclear translocation were decreased in cardiac fibroblasts treated with N-Acetyl-Ser-Asp-Lys-Pro [1]. N-acetyl-seryl-aspartyl-lysyl-proline appears to exert this function by inhibiting the effects of stem cell-specific proliferation stimulators and acting preferentially on quiescent progenitor cells [2] . N-Acetyl-Ser-Asp-Lys-Pro suppresses collagenase expression, and activation is related with increased production of TIMP-1 and TIMP-2. N-Acetyl-Ser-Asp-Lys-Pro normalizes IL-1β-mediated increases in MMP-2 and MMP-9 activity and MMP-13 expression [3].
|
|---|---|
| ln Vivo |
N-Acetyl-Ser-Asp-Lys-Pro inhibits phenylephrine down-regulation, albuminuria, collagen deposition, and inflammatory cell infiltration that are brought on by hypertension. In hypertensive mice, this may have renoprotective properties [4].
|
| References |
|
| Additional Infomation |
Goralatide is a tetrapeptide that is Ser-Asp-Lys-Pro in which the N-terminal amino group carries an acetyl group. It is selective inhibitor of primitive haematopoietic cell proliferation and exhibits anti-inflammatory, anti-fibrotic, and pro-angiogenic properties. It has a role as an anti-inflammatory agent and a pro-angiogenic agent. It is functionally related to a Ser-Asp-Lys-Pro. It is a conjugate acid of a goralatide(1-).
|
| Molecular Formula |
C20H33N5O9
|
|---|---|
| Molecular Weight |
487.50412
|
| Exact Mass |
487.227
|
| CAS # |
127103-11-1
|
| Related CAS # |
N-Acetyl-Ser-Asp-Lys-Pro acetate;N-Acetyl-Ser-Asp-Lys-Pro TFA
|
| PubChem CID |
65938
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
992.0±65.0 °C at 760 mmHg
|
| Flash Point |
553.7±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.565
|
| LogP |
-1.91
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
34
|
| Complexity |
776
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(NC(C(NC(C(NC(C(N1CCCC1C(O)=O)=O)CCCCN)=O)CC(O)=O)=O)CO)=O
|
| InChi Key |
HJDRXEQUFWLOGJ-AJNGGQMLSA-N
|
| InChi Code |
InChI=1S/C20H33N5O9/c1-11(27)22-14(10-26)18(31)24-13(9-16(28)29)17(30)23-12(5-2-3-7-21)19(32)25-8-4-6-15(25)20(33)34/h12-15,26H,2-10,21H2,1H3,(H,22,27)(H,23,30)(H,24,31)(H,28,29)(H,33,34)/t12-,13-,14-,15-/m0/s1
|
| Chemical Name |
(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0513 mL | 10.2564 mL | 20.5128 mL | |
| 5 mM | 0.4103 mL | 2.0513 mL | 4.1026 mL | |
| 10 mM | 0.2051 mL | 1.0256 mL | 2.0513 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
